CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Treatment for multiple periorbital eccrine hidrocystomas: botulinum toxin A.

Hidrocystomas are relatively common cystic lesions that can display either apocrine or eccrine differentiation. While numerous treatment modalities exist for solitary hidrocystomas including simple excision, electrodesiccation, and CO2 laser, treatment of multiple hidrocystomas can be challenging. A 38-year-old, black female with a 23-year history of multiple periorbital cystic nodules presented to the clinic with the complaint of lesions that were increasing in size and number. Prior treatment included excision resulting in scarring without significant clinical improvement. Initially, incision and drainage was performed with flattening of the cysts; however, the cystic nodules refilled to baseline by 6 weeks. Subsequently, intralesional botulinum toxin type A was offered as an alternate therapy in conjunction with incision and drainage. The patient reported sustained flattening of the lesions at both 1-month and 4-month follow-up appointments. Intralesional botulinum toxin A offers a novel treatment for patients with multiple hidrocystomas that have failed other therapies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app